Oligomer-Targeting Prevention of Neurodegenerative Dementia by Intranasal Rifampicin and Resveratrol Combination – A Preclinical Study in Model Mice

16Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Amyloidogenic protein oligomers are thought to play an important role in the pathogenesis of neurodegenerative dementia, including Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies. Previously we demonstrated that oral or intranasal rifampicin improved the cognition of APP-, tau-, and α-synuclein-transgenic mice by reducing the amount of Aβ, tau, and α-synuclein oligomers in the brain. In the present study, to explore more effective and safer medications for dementia, we tested the drug combination of rifampicin and resveratrol, which is a multifunctional natural polyphenol with the potential to antagonize the adverse effects of rifampicin. The mixture was intranasally administered to APP-, tau-, and α-synuclein-transgenic mice, and their memory and oligomer-related pathologies were evaluated. Compared with rifampicin and resveratrol alone, the combinatorial medicine significantly improved mouse cognition, reduced amyloid oligomer accumulation, and recovered synaptophysin levels in the hippocampus. The plasma levels of liver enzymes, which reflect hepatic injury and normally increase by rifampicin treatment, remained normal by the combination treatment. Notably, resveratrol alone and the combinatorial medicine, but not rifampicin alone, enhanced the levels of brain-derived neurotrophic factor (BDNF) and its precursor, pro-BDNF, in the hippocampus. Furthermore, the combination showed a synergistic effect in ameliorating mouse cognition. These results show the advantages of this combinatorial medicine with regards to safety and effectiveness over single-drug rifampicin. Our findings may provide a feasible means for the prevention of neurodegenerative dementia that targets toxic oligomers.

References Powered by Scopus

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology

1320Citations
N/AReaders
Get full text

Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain

918Citations
N/AReaders
Get full text

Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice

696Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Curcumin can improve Parkinson's disease via activating BDNF/PI3k/Akt signaling pathways

62Citations
N/AReaders
Get full text

Heterogeneous Tau Oligomers as Molecular Targets for Alzheimer’s Disease and Related Tauopathies

14Citations
N/AReaders
Get full text

Does resveratrol improve cognition in humans? A scientometric study to an in-depth review

9Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Umeda, T., Sakai, A., Shigemori, K., Yokota, A., Kumagai, T., & Tomiyama, T. (2021). Oligomer-Targeting Prevention of Neurodegenerative Dementia by Intranasal Rifampicin and Resveratrol Combination – A Preclinical Study in Model Mice. Frontiers in Neuroscience, 15. https://doi.org/10.3389/fnins.2021.763476

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

58%

Lecturer / Post doc 3

25%

Professor / Associate Prof. 1

8%

Researcher 1

8%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 4

44%

Medicine and Dentistry 3

33%

Computer Science 1

11%

Nursing and Health Professions 1

11%

Article Metrics

Tooltip
Mentions
Blog Mentions: 3
News Mentions: 11
Social Media
Shares, Likes & Comments: 74

Save time finding and organizing research with Mendeley

Sign up for free